TDP‑43 is a DNA‑ and RNA‑binding protein that belongs to highly conserved heterogeneous nuclear ribonucleoprotein (hnRNP) family. In the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), TDP‑43 accumulates in the form of insoluble cytoplasmic aggregates, which represent a key pathological hallmark.
TDP‑43 is a primarily nuclear protein composed of a structured N‑terminal domain, two highly conserved RNA‑recognition motifs, and an intrinsically disordered C‑terminal domain that is prone to structural rearrangements and proteolytic cleavage. Under physiological conditions, TDP‑43 plays a key role in regulating of RNA metabolism.
Deamidation, the conversion of asparagine or glutamine into aspartate or glutamate, is a common post‑translational modification that can alter protein stability, solubility, and function. These changes may influence the pathological behaviour of TDP‑43.
In the experimental part of the study, we generated four deamidation mutants of TDP‑43 using in vivo assembly (IVA) cloning. The recombinant proteins were expressed in Escherichia coli BL21[DE3] using autoinduction, and protein expression before and after induction was analysed with NaDS‑PAGE and western blotting.
The results confirm thrsuccessful preparation and expression of all four deamidated TDP‑43 mutants, representing an important first step toward understanding how deamidation may influence the structure and stability of TDP‑43. These mutants provide a valuable foundation for future studies of TDP-43 pathogenesis.
|